1. Home
  2. NEWP vs LYEL Comparison

NEWP vs LYEL Comparison

Compare NEWP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Pacific Metals Corp.

NEWP

New Pacific Metals Corp.

HOLD

Current Price

$5.87

Market Cap

1.3B

Sector

N/A

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$11.96

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEWP
LYEL
Founded
1972
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
320.1M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
NEWP
LYEL
Price
$5.87
$11.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$6.00
$30.60
AVG Volume (30 Days)
592.7K
92.9K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$11.47
52 Week High
$7.55
$45.00

Technical Indicators

Market Signals
Indicator
NEWP
LYEL
Relative Strength Index (RSI) 42.84 35.26
Support Level $3.44 $11.59
Resistance Level $6.31 $14.14
Average True Range (ATR) 0.41 0.81
MACD -0.20 -0.30
Stochastic Oscillator 3.68 4.37

Price Performance

Historical Comparison
NEWP
LYEL

About NEWP New Pacific Metals Corp.

New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: